Home  Partnering Key areas of partnering interest
|
|
| Respiratory & Inflammation |
| Key areas of partnering interest |
|
|
Many challenges remain in respiratory medicine, such as the development of novel drugs that interfere with the underlying disease processes, and the improvement of existing medications and delivery devices to simplify disease management for the patient. Already a leader in the treatment of asthma, AstraZeneca is expanding its range by developing novel treatments in other areas of inflammatory disease areas such as rheumatology. Respiratory |
|---|
COPD and Asthma
- Advanced clinical programmes
- Early stage alliances focused on:
- Control of exacerbations – targets: inflammation, rhinovirus
- Muscle wasting and dysfunction
- Facilitating lung recovery – targets: inflammation, mucus destruction, remodelling
Novel inhalation approaches or other delivery concepts
|
Inflammation |
|---|
Rheumatology
- Agents in clinical development with patient efficacy data that are differentiated from marketed products, specifically in rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
- Early stage alliances in rheumatology
|
Lena Mårtensson, Pre-clinical
Pontus Nilsson, Clinical – respiratory
Sue Silverman, Clinical – inflammation
E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names
- Replace å with a |
|
|
|
|